Advertisement

Chemoproteomic Characterization of Protein Kinase Inhibitors Using Immobilized ATP

  • James S. Duncan
  • Timothy A. J. Haystead
  • David W. LitchfieldEmail author
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 795)

Abstract

Protein kinase inhibitors have emerged as indispensable tools for the elucidation of the biological functions of specific signal transduction pathways and as promising candidates for molecular-targeted therapy. However, because many protein kinase inhibitors are ATP-competitive inhibitors targeting the catalytic site of specific protein kinases, the large number of protein kinases that are encoded within eukaryotic genomes and the existence of many other cellular proteins that bind ATP result in the prospect of off-target effects for many of these compounds. Many of the potential off-target effects remain unrecognized because protein kinase inhibitors are often developed and tested primarily on the basis of in vitro assays using purified components. To overcome this limitation, we describe a systematic approach to characterize ATP-competitive protein kinase inhibitors employing ATP-sepharose to capture the purine-binding proteome from cell extracts. Protein kinase inhibitors can be used in competition experiments to prevent binding of specific cellular proteins to ATP-sepharose or to elute bound proteins from ATP-sepharose. Collectively, these strategies can enable validation of interactions between a specific protein kinase and an inhibitor in complex mixtures and can yield the identification of inhibitor targets.

Key words

Protein kinase inhibitors Chemoproteomics ATP-sepharose Protein kinase CK2 Mass spectrometry 2D Gel electrophoresis 

Notes

Acknowledgments

We are grateful to Laszlo Gyenis, John Lenehan, Maria Bretner, and Lee Graves for assistance and helpful discussions. We would also like to thank Cunjie Zhang and Christopher Ward in the Functional Proteomic Facility and Kristina Jurcic and Ken Yeung within the MALDI Mass Spectrometry Facility in the Schulich School of Medicine & Dentistry at the University of Western Ontario. Our work on the characterization of CK2 inhibitors and the development of functional proteomics strategies has been funded by the Canadian Cancer Society Research Institute and the Canadian Institutes of Health Research. James Duncan was supported by a Canada Graduate Scholarship from the Canadian Institutes of Health Research (CIHR) and by the CIHR-University of Western Ontario Strategic Training Initiative in Cancer Research and Technology Transfer.

References

  1. 1.
    Noble M.E., Endicott J.A., and Johnson L.N. (2004) Protein kinase inhibitors: insights into drug design from structure. Science 303, 1800–1805.PubMedCrossRefGoogle Scholar
  2. 2.
    Cohen P. (2002) Protein kinases--the major drug targets of the twenty-first century? Nat. Rev. Drug Discov. 1, 309–315.PubMedCrossRefGoogle Scholar
  3. 3.
    Sawyers C.L. (2003) Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Genes Dev. 17, 2998–3010.PubMedCrossRefGoogle Scholar
  4. 4.
    Lydon N.B., and Druker B.J. (2004) Lessons learned from the development of imatinib. Leuk. Res. 28, S29–38.PubMedCrossRefGoogle Scholar
  5. 5.
    Manning G., Whyte D.B., Martinez R., Hunter T., and Sudarsanam S. (2002) The protein kinase complement of the human genome. Science 298, 1912–1934.PubMedCrossRefGoogle Scholar
  6. 6.
    Bain J., Plater L., Elliott M., Shpiro N., Hastie C.J., McLauchlan H., Klevernic I., Arthur J.S., Alessi D.R., and Cohen P. (2007) The selectivity of protein kinase inhibitors: a further update. Biochem. J. 408, 297–315.PubMedCrossRefGoogle Scholar
  7. 7.
    Bain J., McLauchlan H., Elliott M., and Cohen P. (2003) The specificities of protein kinase inhibitors: an update. Biochem. J. 371, 199–204.PubMedCrossRefGoogle Scholar
  8. 8.
    Davies S.P., Reddy H., Caivano M., and Cohen P. (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351, 95–105.PubMedCrossRefGoogle Scholar
  9. 9.
    Pagano M.A., Bain J., Kazimierczuk Z., Sarno S., Ruzzene M., Di Maira G., Elliott M., Orzeszko A., Cozza G., Meggio F., and Pinna L.A. (2008) The selectivity of inhibitors of protein kinase CK2: an update. Biochem. J. 415, 353–365.PubMedCrossRefGoogle Scholar
  10. 10.
    Graves P.R., Kwiek J.J., Fadden P., Ray R., Hardeman K., Coley A.M., Foley M., and Haystead T.A. (2002) Discovery of novel targets of quinoline drugs in the human purine binding proteome. Mol. Pharmacol. 62, 1364–1372.PubMedCrossRefGoogle Scholar
  11. 11.
    Haystead T.A. (2006) The purinome, a complex mix of drug and toxicity targets. Curr. Top. Med. Chem. 6, 1117–1127.PubMedCrossRefGoogle Scholar
  12. 12.
    Duncan J.S., Gyenis L., Lenehan J., Bretner M., Graves L.M., Haystead T.A., and Litchfield D.W. (2008) An unbiased evaluation of CK2 inhibitors by chemoproteomics: characterization of inhibitor effects on CK2 and identification of novel inhibitor targets. Mol. Cell Proteomics 7, 1077–1088.PubMedCrossRefGoogle Scholar
  13. 13.
    Landesman-Bollag E., Romieu-Mourez R., Song D.H., Sonenshein G.E., Cardiff R.D., and Seldin D.C. (2001) Protein kinase CK2 in mammary gland tumorigenesis. Oncogene 20, 3247–3257.PubMedCrossRefGoogle Scholar
  14. 14.
    Litchfield D.W. (2003) Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem. J. 369, 1–15.PubMedCrossRefGoogle Scholar
  15. 15.
    Duncan J.S., and Litchfield D.W. (2008) Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2. Biochim. Biophys. Acta 1784, 33–47.PubMedGoogle Scholar
  16. 16.
    Sarno S., and Pinna L.A. (2008) Protein kinase CK2 as a druggable target. Mol. Biosyst. 4, 889–894.PubMedCrossRefGoogle Scholar
  17. 17.
    Sarno S., Reddy H., Meggio F., Ruzzene M., Davies S.P., Donella-Deana A., Shugar D., and Pinna L.A. (2001) Selectivity of 4,5,6,7-tetrabromobenzotriazole, an ATP site-directed inhibitor of protein kinase CK2 (‘casein kinase-2’). FEBS Lett. 496, 44–48.PubMedCrossRefGoogle Scholar
  18. 18.
    Zien P., Duncan J.S., Skierski J., Bretner M., Litchfield D.W., and Shugar D. (2005) Tetrabromobenzotriazole (TBBt) and tetrabromobenzimidazole (TBBz) as selective inhibitors of protein kinase CK2: evaluation of their effects on cells and different molecular forms of human CK2. Biochim. Biophys. Acta 1754, 271–280.PubMedGoogle Scholar
  19. 19.
    Pagano M.A., Meggio F., Ruzzene M., Andrzejewska M., Kazimierczuk Z., Pinna L.A. (2004) 2-Dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole: a novel powerful and ­selective inhibitor of protein kinase CK2. Biochem. Biophys. Res. Commun. 321, 1040–1044.PubMedCrossRefGoogle Scholar
  20. 20.
    Haystead C.M., Gregory P., Sturgill T.W., and Haystead T.A. (1993) Gamma-phosphate-linked ATP-sepharose for the affinity purification of protein kinases. Rapid purification to homogeneity of skeletal muscle mitogen-­activated protein kinase kinase. Eur. J. Biochem. 214, 459–467.PubMedCrossRefGoogle Scholar
  21. 21.
    Gietz R.D., Graham K.C., and Litchfield D.W. (1995) Interactions between the subunits of casein kinase II. J. Biol. Chem. 270, 13017–13021.PubMedCrossRefGoogle Scholar
  22. 22.
    Battistutta R., De Moliner E., Sarno S., Zanotti G., and Pinna L.A. (2001) Structural features underlying selective inhibition of protein kinase CK2 by ATP site-directed tetrabromo-2-­benzotriazole. Protein Sci. 10, 2200–2206.PubMedCrossRefGoogle Scholar
  23. 23.
    Sarno S., de Moliner E., Ruzzene M., Pagano M.A, Battistutta R., Bain J., Fabbro D., Schoepfer J., Elliott M., Furet P., Meggio F., Zanotti G., Pinna L.A. (2003) Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA). Biochem. J. 374, 639–646.PubMedCrossRefGoogle Scholar
  24. 24.
    Graham K.C., and Litchfield D.W. (2000) The regulatory beta subunit of protein kinase CK2 mediates formation of tetrameric CK2 complexes. J. Biol. Chem. 275, 5003–5010.PubMedCrossRefGoogle Scholar
  25. 25.
    Smith P.K., Krohn R.I., Hermanson G.T., Mallia A.K., Gartner F.H., Provenzano M.D., Fujimoto E.K., Goeke N.M., Olson B.J., and Klenk D.C. (1985) Measurement of protein using bicinchoninic acid. Anal. Biochem. 150, 76–85.PubMedCrossRefGoogle Scholar
  26. 26.
    Bradford M.M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248–254.PubMedCrossRefGoogle Scholar
  27. 27.
    Towbin H., Staehelin T., and Gordon J. (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA. 76, 4350–4354.PubMedCrossRefGoogle Scholar
  28. 28.
    Laemmli UK. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680–685.PubMedCrossRefGoogle Scholar
  29. 29.
    Görg A., Obermaier C., Boguth G., Harder A., Scheibe B., Wildgruber R., and Weiss W. (2000) The current state of two-dimensional electrophoresis with immobilized pH gradients. Electrophoresis 21, 1037–1053.PubMedCrossRefGoogle Scholar
  30. 30.
    Görg A., Drews O., Lück C., Weiland F., and Weiss W. (2009) 2-DE with IPGs. Electrophoresis 30, S122–132.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • James S. Duncan
    • 1
    • 2
  • Timothy A. J. Haystead
    • 3
  • David W. Litchfield
    • 1
    Email author
  1. 1.Department of Biochemistry, Schulich School of Medicine & DentistryUniversity of Western OntarioLondonCanada
  2. 2.Department of PharmacologyUniversity of North Carolina, School of MedicineChapel HillUSA
  3. 3.Department of Pharmacology & Cancer BiologyDuke University Medical CentreDurhamUSA

Personalised recommendations